Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Bailly

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Journal of Viral Hepatitis|June 10, 2000
Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapyP Pradat, P Chossegros, F Bailly, et al.
Journal of Viral Hepatitis|December 22, 1999
A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 groupT Poynard, V Daurat, S Chevret, et al.
European Journal of Gastroenterology & Hepatology|July 27, 2000
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative ResearchS Touzet, L Kraemer, C Colin, et al.
Hepatology (Baltimore, Md.)|March 21, 1998
Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferonJ P Zarski, M Maynard-Muet, S Chousterman, et al.
Journal of Viral Hepatitis|May 20, 2003
Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled studyI Portal, M Bourlière, P Halfon, et al.
HIV Medicine|December 8, 2017
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)E Rosenthal, C Fougerou-Leurent, A Renault, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Journal of Viral Hepatitis|June 10, 2000
Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapyP Pradat, P Chossegros, F Bailly, et al.
Journal of Viral Hepatitis|December 22, 1999
A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 groupT Poynard, V Daurat, S Chevret, et al.
European Journal of Gastroenterology & Hepatology|July 27, 2000
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative ResearchS Touzet, L Kraemer, C Colin, et al.
Hepatology (Baltimore, Md.)|March 21, 1998
Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferonJ P Zarski, M Maynard-Muet, S Chousterman, et al.
Journal of Viral Hepatitis|May 20, 2003
Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled studyI Portal, M Bourlière, P Halfon, et al.
HIV Medicine|December 8, 2017
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)E Rosenthal, C Fougerou-Leurent, A Renault, et al.
Pageof 8